NCT02152774View on ClinicalTrials.gov

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma

PHASE2UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 28, 2015

Conditions
Chronic Angle-closure Glaucoma
Interventions
DRUG

Rho-Kinase Inhibitor

Trial Locations (1)

10003

Glaucoma Associates of New York, New York

Sponsors
All Listed Sponsors
lead

New York Glaucoma Research Institute

OTHER